資料載入中.....
|
請使用永久網址來引用或連結此文件:
https://irlib.pccu.edu.tw/handle/987654321/24020
|
| 題名: | A New Drug Design Targeting the Adenosinergic System for Huntington's Disease |
| 作者: | ng, NK (Huang, Nai-Kuei)
Lin, JH (Lin, Jung-Hsin)
Lin, JT (Lin, Jiun-Tsai)
Lin, CI (Lin, Chia-I)
Liu, EMW (Liu, Eric Minwei)
Lin, CJ (Lin, Chun-Jung)
Chen, WP (Chen, Wan-Ping)
Shen, YC (Shen, Yuh-Chiang)
Chen, HM (Chen, Hui-Mei)
Chen, JB (Chen, Jhih-Bin)
Lai, HL (Lai, Hsing-Lin)
Yang, CW (Yang, Chieh-Wen)
Chiang, MC (Chiang, Ming-Chang)
Wu, YS (Wu, Yu-Shuo)
Chang, C (Chang, Chen)
Chen, JF (Chen, Jiang-Fan)
Fang, JM (Fang, Jim-Min)
Lin, YL (Lin, Yun-Lian)
Chern, YJ (Chern, Yijuang) |
| 貢獻者: | Grad Inst Biotechnol |
| 關鍵詞: | DEPRIVATION-INDUCED APOPTOSIS
RAT PHEOCHROMOCYTOMA
CELLS
SITE-DIRECTED MUTAGENESIS
TRANSGENIC MOUSE MODEL
A(2A) RECEPTOR AGONIST
CENTRAL-NERVOUS-SYSTEM
GASTRODIA-ELATA BLUME
UREA CYCLE DEFICIENCY
LIGAND RECOGNITION
SERUM DEPRIVATION |
| 日期: | 2011-06-21 |
| 上傳時間: | 2013-01-16 16:04:19 (UTC+8) |
| 摘要: | Background: Huntington's disease (HD) is a neurodegenerative disease caused by a CAG trinucleotide expansion in the Huntingtin (Htt) gene. The expanded CAG repeats are translated into polyglutamine (polyQ), causing aberrant functions as well as aggregate formation of mutant Htt. Effective treatments for HD are yet to be developed.
Methodology/Principal Findings: Here, we report a novel dual-function compound, N-6-(4-hydroxybenzyl) adenine riboside (designated T1-11) which activates the A(2A)R and a major adenosine transporter (ENT1). T1-11 was originally isolated from a Chinese medicinal herb. Molecular modeling analyses showed that T1-11 binds to the adenosine pockets of the A(2A)R and ENT1. Introduction of T1-11 into the striatum significantly enhanced the level of striatal adenosine as determined by a microdialysis technique, demonstrating that T1-11 inhibited adenosine uptake in vivo. A single intraperitoneal injection of T1-11 in wildtype mice, but not in A(2A)R knockout mice, increased cAMP level in the brain. Thus, T1-11 enters the brain and elevates cAMP via activation of the A(2A)R in vivo. Most importantly, addition of T1-11 (0.05 mg/ml) to the drinking water of a transgenic mouse model of HD (R6/2) ameliorated the progressive deterioration in motor coordination, reduced the formation of striatal Htt aggregates, elevated proteasome activity, and increased the level of an important neurotrophic factor (brain derived neurotrophic factor) in the brain. These results demonstrate the therapeutic potential of T1-11 for treating HD.
Conclusions/Significance: The dual functions of T1-11 enable T1-11 to effectively activate the adenosinergic system and subsequently delay the progression of HD. This is a novel therapeutic strategy for HD. Similar dual-function drugs aimed at a particular neurotransmitter system as proposed herein may be applicable to other neurotransmitter systems (e. g., the dopamine receptor/dopamine transporter and the serotonin receptor/serotonin transporter) and may facilitate the development of new drugs for other neurodegenerative diseases. |
| 關聯: | PLOS ONE Volume: 6 Issue: 6 Article Number: e20934 |
| 顯示於類別: | [生物科技研究所 ] 期刊論文
|
文件中的檔案:
| 檔案 |
描述 |
大小 | 格式 | 瀏覽次數 |
|---|
| index.html | | 0Kb | HTML | 683 | 檢視/開啟 |
|
在CCUR中所有的資料項目都受到原著作權保護.
|
